Učitavanje...
Differentiating mTOR Inhibitors in Renal Cell Carcinoma
PI3K/Akt/mTOR signalling is dysregulated in many cancers, including renal cell carcinoma (RCC), and activation of this pathway has been suggested to correlate with aggressive behavior and poor prognosis in RCC tumors. mTOR inhibition plays a principal role in the targeted treatment of many cancer ty...
Spremljeno u:
| Izdano u: | Cancer Treat Rev |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2013
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4957946/ https://ncbi.nlm.nih.gov/pubmed/23433636 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ctrv.2012.12.015 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|